Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc.
By BUSINESS WIRE
Posted 09:13 PM ET
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that a federal jury in Tacoma, Washington found that Illumina’s BeadChip array product infringed U.S. Patent No. 6,951, 682, asserted by Syntrix Biosystems, Inc. The federal jury ordered Illumina to pay approximately $96 million in damages to Syntrix based on a royalty rate of six percent for BeadChip products sold by Illumina from 2005 through May 2012. United States District Court Judge Benjamin H. Settle, however, dismissed from the case claims that Illumina’s alleged infringement was willful and that Illumina misappropriated Syntrix’s trade secrets. The Syntrix patent expires on September 17, 2019.
Illumina continues to believe that Syntrix’s claims are without merit. Illumina intends to file post-trial motions asking the court to vacate the jury’s finding and to rule as a matter of law that the BeadChip does not infringe Syntrix’s patent.
Jay Flatley, Illumina’s President and CEO, stated, “We strongly disagree with this verdict and plan to appeal the present finding of infringement. In the meantime, we will continue to sell the products that are the subject of this suit and no damages will be payable to Syntrix until all appropriate appeals have been taken, which may take a number of years.” Mr. Flatley continued, “Our BeadChip products are based on Dr. David Walt’s technology that was licensed from Tufts University when Illumina was founded in 1998. Like many other companies, we respect the valid and enforceable intellectual property rights of others. Consistent with our policy, we believe we acted properly with respect to the Syntrix ‘682 patent. We continue to feel very strongly about our position that Syntrix’s allegations are without merit and that, ultimately, our position will be vindicated.”
Personalis Awarded Contract from VA Million Veteran Program –
Whole Genome Sequencing and Data Analysis for Over 1,000 Individuals
Menlo Park, CA – March 11, 2013 –The US Department of Veterans Affairs (VA) has awarded its first contract for whole genome DNA sequencing and data analysis to Personalis, Inc., of Menlo Park, CA. The contract will utilize samples from several VA sources, including from the Million Veteran Program (MVP). Using its secure computing facility and proprietary algorithms, Personalis will QC all raw data, call variants against an advanced human reference sequence, annotate both SNV/indels and SVs, and provide genetic analyses to help confirm sample / data chain of custody. Personalis plans to subcontract the laboratory genetic analysis, including both DNA sequencing and genome-scale genotyping, to Illumina, Inc., of San Diego, CA.
Personalis CEO John West said “The VA’s MVP has the potential to be the largest and most important medical sequencing effort in the world. We are thrilled that the VA has chosen Personalis for the DNA sequencing and analysis on this project. Our emphasis is on delivering an accurate and comprehensive sequencing solution for the VA.”